Discuss the scientific challenges in developing a vaccine against a multi-serotype pathogen like dengue, with reference to India's recently approved Qdenga vaccine.

Q. Discuss the scientific challenges in developing a vaccine against a multi-serotype pathogen like dengue, with reference to India's recently approved Qdenga vaccine. (15 marks, 250-350 words)

Dengue is caused by four antigenically distinct but related serotypes (DENV-1 to DENV-4). A vaccine must therefore protect against all four at once and equally — a demand that makes dengue among the hardest immunological targets, as India's newly approved Qdenga (TAK-003) illustrates.

Why multi-serotype pathogens resist vaccine design - Infection with one serotype gives lasting immunity only to that serotype; cross-protection is partial and temporary, and a second infection by a different serotype carries greater risk of severe dengue [3]. - Hence a partially effective vaccine can itself be harmful — by mimicking a first infection, it may prime an enhanced response (antibody-dependent enhancement) to a serotype it does not cover. - Building four components into one formulation invites immune interference, where the strongest component dominates and suppresses the others.

Qdenga: the design trade-off made visible - It is a live-attenuated tetravalent vaccine built on a DENV-2 genomic backbone, with genetic components of the other three serotypes inserted [1]. - Efficacy is consequently uneven: strongest against DENV-2, moderate against DENV-1, while in baseline seronegative recipients no efficacy was demonstrated against DENV-3, and low case incidence precluded assessment against DENV-4 [2].

Challenges in generating evidence - Endpoints must be broken down by serotype and by prior-exposure status, requiring large trials and multi-year follow-up; rare serotypes simply may not circulate enough to be measured [2]. - India reported over 1.2 lakh dengue cases in 2025, with nearly all States affected and serotype dominance varying regionally [4] — so protection may differ across the country.

Regulators have responded by managing, not ignoring, this uncertainty: CDSCO cleared Qdenga for ages 4–60 years, two 0.5 ml doses three months apart, after evaluation under the Drugs and Cosmetics Act, 1940 [1], with a mandatory post-marketing study. Coupled with strengthened vector control, serotype surveillance and transparent risk communication, such conditional, evidence-tracking approvals let India gain from a partially protective tool while science closes the remaining gaps.

(~325 words)

Sources: 1. CDSCO Approves India's First Dengue Vaccine, Strengthening National Dengue Prevention Efforts — PIB, Ministry of Health & Family Welfare — Qdenga's live-attenuated tetravalent design on a DENV-2 backbone, age group 4–60 years, two-dose schedule, statutory basis of approval 2. Dengue vaccine (TAK-003): GRADE tables, WHO Vaccine Position Paper (2024) — serotype- and serostatus-specific efficacy, absence of demonstrated efficacy against DENV-3 in seronegatives and non-assessability of DENV-4 3. Dengue and severe dengue — WHO Fact Sheet — higher risk of severe dengue on second infection 4. Dengue Situation in India — National Center for Vector Borne Diseases Control (NCVBDC), MoHFW — national dengue caseload and nationwide spread